Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry

OBJECTIVE: To explore differences in response to a low dosage regimen of infliximab with an escalating dosage in comparison to a standard dosage of etanercept and adalimumab in patients with psoriatic arthritis (PsA). METHODS: Biologically naïve PsA patients who were beginning anti-TNF-α therapy wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Gudbjornsson, Bjorn, Geirsson, Arni Jon, Krogh, Niels Steen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942167/
https://www.ncbi.nlm.nih.gov/pubmed/29765870
http://dx.doi.org/10.2147/PTT.S161522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942167/
https://www.ncbi.nlm.nih.gov/pubmed/29765870
http://dx.doi.org/10.2147/PTT.S161522

Ejemplares similares